Work

Melatonin Enhances the Efficacy of Cdk4/6 Inhibitor in Breast Cancer Cells Via Down-Regulating the Expression of Cyclind1

Year: 2024

Type: article

Abstract: Breast Cancer (BC) is the most common malignancy and cause of death among women. CDK4/6 inhibitor-Palbociclib (PD) isethionate is a new chemotherapeutic agent in the treatment of breast cancer that works through blocking retinoblastoma phosphorylation protein and regulating the retinoblastoma (RB)-E2F pathway to inhibit cell cycle in the G0/G1 phase. However, the toxicity and resistance of PD are the primary limiting factors of this therapeutic effect. Melatonin (MLT) exerts anti-tumor activity in BC and arrests the cell cycle in the G0/G1 phase.

Source: Biomedical Journal of Scientific & Technical Research

DOI: 10.26717/bjstr.2024.59.009367

Author: Yuhui Yuan

Institutions: Dalian Medical University, Second Affiliated Hospital of Dalian Medical University

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: National Natural Science Foundation of China, Dalian Medical University